歡迎來到 BIO Asia-Taiwan，親自認識 Invion（澳洲上市公司，股票代碼 ASX: IVX）執行主席兼執行長 Thian Chew 教授！
 
Invion 是一家臨床階段的生技公司，致力於開發下一代光動力治療（Photodynamic Therapy, PDT）技術——Photosoft，用於治療多種癌症與傳染性疾病。
 
Invion 近期公佈了第二期攝護腺癌臨床試驗的正面結果，反應率達 40%，且安全性表現良好。目前也正進行皮膚癌的一期/二期臨床試驗，並預計在未來 12 至 24 個月內展開更多針對其他癌症的試驗。
 
此外，Invion 已與韓國 Hanlim Pharma 與 Dr. inB 簽署合作協議，對方將出資並進行研究，探索使用 Photosoft 治療腦部惡性腫瘤（膠質母細胞瘤 GBM）、食道癌及人類乳突病毒（HPV）相關疾病的潛力。
 
Invion 的研究合作夥伴——彼得·麥卡倫癌症中心（Peter MacCallum Cancer Centre）與哈德遜醫學研究所（Hudson Institute of Medical Research）所進行的前臨床研究顯示，該技術可完全抑制多種癌症（例如三陰性乳癌與卵巢癌），並能激發人體免疫系統持續對抗癌細胞。
 
Invion 已開發出一系列受專利保護的化合物，其主要藥物候選為 INV043，一種新型光敏劑，具有同時作為治療與診斷工具的潛力。

Come and meet Prof. Thian Chew, the Executive Chair and CEO of Australian-listed Invion (ASX: IVX) at BIO Asia-Taiwan! Invion is a clinical-stage company developing the next-generation Photodynamic Therapy (PDT), called Photosoft, for the treatment of a range of cancers and infectious diseases.

Invion released positive results from a Phase II prostate cancer trial with a 40% response rate and a strong safety profile. It is undertaking a Phase I/II trial on skin cancer with more trials to treat other cancers scheduled over the next 12-24 months.

Additionally, Invion signed agreements with Hanlim Pharma and Dr. inB.

They will fund and undertake studies using Photosoft to treat brain malignancy GBM, oesophageal cancer and Human Papilloma Virus (HPV).

Pre-clinical results undertaken by Invion's research partners, the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research, showed that the technology completely regressed a range of cancers, such as triple negative breast and ovarian cancers, and stimulated the body's immune system to continue fighting the cancer.

Invion has developed a portfolio of patent protected compounds. Its lead drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.